SBIR/STTR Research Award

NASAL CONTOUR PACK FOR EPISTAXIS

Award identifier a7c223515a70eb44f90341b6647871642d448a4a07c12f27239464805cb3f8a8Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$99,495

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Rose Biomedical Development Corporation
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

Epitaxis, otherwise known as nosebleed, is a common occurrence that typically responds to home treatment. Some cases, however, do not respond and a significant number of patients require emergency room treatment. In severe cases, hospital admittance and time in intensive care are necessary. Several methods of treatment have evolved for treatment of epistaxis: 1) gauze packing, 2) balloon and 3) desiccated sponge packs. Each strategy has strengths, but also weaknesses. Gauze packing decreases blood oxygen levels and is extremely painful, requiring administration of narcotics. Nasal balloons resist conformation to the intricacies of the nasal cavity. Desiccated sponges are solid and immalleable during insertion, often damaging the nasal mucosa. RBDC proposes to develop and test the Nasal Contour Pack (C-Pack). The C-Pack has a soft PVC tube base for easy insertion and removal with two thin, soft plastic bags mounted on top of the tube. Once inserted, the bags can be inflated to create sufficient pressure to stop the bleed. The soft bags will work into the various crevices, create even pressure, will insert easily, can be deflated for easy removal. It will be much less painful, will not require narcotics, and have a channel to provide supplemental oxygen. PROPOSED COMMERCIAL APPLICATIONS: Epistaxis remains one of the most common acute ENT disorders resulting in hospital admissions. Approximately 5-10% of the population experience an episode of active nasal bleed each year. Approximately 10% of these patients visit a physician and one in 10 will require hospitalization. A device that imposes none of the disadvantages of current technology, that can be inserted in an exact and simple manner, is effective as initial intervention and that could be produced at no greater expense than existing devices, would find a prominent place within the market.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.